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Abstract
Background Recently published data indicate that the
inﬂammation in Crohn’s disease (CD) may be accompa-
nied by elevated levels of matrix metalloproteinases.
Aims The goals of the present study were the estimation
of MMP-3 and -9 concentrations in sera of children with
Crohn’s disease, the examination of correlation between
the concentrations of MMP-3 and -9 and clinical activity of
the disease in the relation to the control group and the
evaluation of the utility of MMP-3 and -9 concentration
measurements as markers of disease activity.
Methods Serum concentrations of MMP-3 and -9 were
estimated in 82 children (45 CD patients divided into
severe, moderate and mild subgroups; 37 controls) and
correlated with disease activity estimated by the Pediatric
Crohn’s Disease Activity Index (PCDAI), CRP, seromu-
coid and ESR.
Results Mean MMP-3 concentrations were: 2.49 ng/ml
(95% CI: 1.76–3.52) for mild, 16.44 ng/ml (95% CI:
10.34–26.15)formoderate,5.25 ng/ml(95%CI:2.73–10.11)
for severe CD and 1.95 ng/ml (95% CI: 1.53–2.48) for the
control group (differences between all three groups were
statistically signiﬁcant; P\0.001). Median MMP-9 con-
centrations were: 2.14 ng/ml (95% CI: 0–8.9) for mild,
14.21 ng/ml (95% CI: 4.53–21.48) for moderate, 42.2 ng/ml
(95% CI: 5.74–61.27) for severe CD and 1.3 ng/ml (95% CI:
0.7–2.18) for the control group. MMP-9 concentrations in
moderate and severe CD differed from the concentrations in
mild CD (P = 0.002) and control group (P = 0.0001).
MMP-3 concentration signiﬁcantly correlated with MMP-9,
PCDAI and ESR, while MMP-9 concentration signiﬁcantly
positively correlated with MMP-3, PCDAI, and CRP. Diag-
nostic utilities of the tests were: MMP-3 accuracy 75%,
positive likelihood ratio (LR?) = 4.11 and negative likeli-
hood ratio (LR-) = 0.51, sensitivity 56%, speciﬁcity 87%,
Youdenindex0.43;forMMP-9,accuracy73%,LR?=5.14
and LR-=0.50, sensitivity 56%, speciﬁcity 89%, Youden
index 0.45; and for CRP, accuracy 74%, LR?=8.56 and
LR-=0.54,sensitivity49%,speciﬁcity94%,Youdenindex
0.43.
Conclusions MMP-9serumconcentrationincreasingalong
withtheactivityofthedisease,exhibitinghighspeciﬁcityand
correlatingwellwith theindices ofinﬂammationmight beof
better usefulness in the prediction of CD activity status in
children than MMP-3.
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Introduction
Matrix metalloproteinases (MMPs) are a group of zinc-
dependent endopeptidases participating in the rearrange-
ment and degradation of extracellular elements of con-
nective tissue [1, 2]. The activity of metalloproteinases is
under multilevel regulation, and their physiological equi-
librium is tightly balanced by the interactions between
activating factors and inhibitors, among which are tissue
inhibitors of metalloproteinases (TIMPs) [2, 3]. A distur-
bance in this balance as well as in the formation and
degradation of MMPs results in the enhancement of
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nents. The changes in MMPs concentration reﬂecting the
state of their activity have been demonstrated in many
pathological processes such as cardiovascular disease [4],
rheumatoid arthritis [5], initiation and progression of var-
ious cancers [6–11], and initiation and maintenance of
inﬂammatory processes including inﬂammatory bowel
disease (IBD) [12–14]. The destruction and rearrangement
of intestinal tract wall observed in IBD raises questions as
to the role which MMPs could play in the etiopathogenesis
of IBD. Experimental models of induced bowel inﬂam-
mation have demonstrated the elevation of MMPs in the
tissues affected by pathological processes [15, 16]. A
growing body of evidence, coming from both animal and
human studies, points towards MMP-3 and -9 as the key
players in the loss of intestinal epithelium integrity
observed in the development of IBD [2, 12, 15, 17–20].
Therefore, in the face of the increasing incidence of IBD
[21–24], a possibility of modulation and monitoring the
disease process by an inﬂuence on the activity of these zinc
endopeptidases is gaining increasing attention [2, 16, 19,
25–27].
However, most of the studies conducted so far are
dealing with the changes of the metalloproteinases on the
tissue level and there are only scarce reports indicating
whether these changes are reﬂected on the systemic level,
and on the possibility of diagnostic usefulness of metallo-
proteinases in IBD management.
The goals of the present study were: the estimation of
MMP-3 and -9 concentrations in sera of children with
Crohn’s disease, the examination of correlation between
the concentrations of MMP-3 and -9 and clinical activity of
the disease in the relation to the control group and the
evaluation of the utility of MMP-3 and -9 concentration
measurements as markers of disease activity.
Materials and Methods
The study was conducted prospectively and comprised 45
patients with recognized CD, aged from 2 to 18 years
(mean age 12.69) treated in the Department and Clinic of
Paediatrics, Gastroenterology and Nutrition of Wroclaw
Medical University in the years 2007–2008. The disease
was diagnosed on the basis of the Porto criteria [28], which
included physical examination, ultrasound studies of the
abdomen, endoscopic studies of the alimentary tract, serial
radiologic studies, and histopathological studies of mucosal
specimens of large intestine and biochemical blood tests.
Based on Montreal criteria [29] in a majority of patients
ileocaecal and large intestine types of CD were recognized.
The patients presented type B1 (nonstricturing, nonpene-
trating) with the exception of one child with type B2
(stricturing). For disease activity assessment, the Pediatric
Crohn’s Disease Activity Index (PCDAI) proposed by
Hyams et al. [30, 31] was applied. The PCDAI includes
subjective patient reporting of symptoms, physical exami-
nation, nutritional parameters and several common labo-
ratory tests results (hematocrit, erythrocyte sedimentation
rate, albumin). On the basis of calculated index the patients
were classiﬁed into three groups: severe (C51), moderate
(26–50) and mild (B25). The children were treated with
50-aminosalicylate (5-ASA), azathioprine or prednison.
None of the children included in the study received bio-
logical treatment (inﬂiximab, adalimumab), which inhibits
TNF-a and therefore might inﬂuence the level of MMPs. A
control group consisted of 37 children aged from 1 to
18 years (mean age 10.1), hospitalized in the Clinic, in
whom organic diseases as well as metabolic disorders were
excluded on the basis of diagnostic procedures. The chil-
dren included in the control group were diagnosed with
growth failure and functional disorders such as functional
dyspepsia, irritable bowel syndrome and functional con-
stipation. Characteristics of the study population are pre-
sented in Table 1.
Blood samples were drawn by venous puncture in a
fasting state in the morning of admission to the hospital
before a treatment was started or intensiﬁed (i.e. cortico-
steroids administration). Sera were obtained from clotted
(30 min., room temperature) and centrifuged (15 min,
1,5009g) blood. Serum samples were stored at -80C
until analysis.
MMP-3 and -9 concentrations were estimated by
enzyme double-antibody indirect immunoassays with
Quantikine Human Total MMP-3 Immunoassay and Duo-
Set Human MMP-9/TIMP-1 Complex provided by R&D
Systems (Minneapolis, MN, USA) in accordance with
manufacturer protocol.
Data on C-reactive protein (CRP), seromucoid and
erythrocyte sedimentation rate (ESR) were retrieved from
patients’ medical records.
Statistical Analysis
Serum concentrations of MMP-3 had normal distribution
after log-transformation, while these of MMP-9 had the
skewed distribution as analyzed with D’Agostino–Pearson
test for normality. Therefore, the average concentrations of
MMP-3 are presented as means and MMP-9 as median
values, both accompanied by 95% conﬁdence interval (95%
CI). Homogeneity of variances was tested with Levene’s
test. The signiﬁcance of differences between groups was
examined with t test for independent samples with Welsh
correction if necessary or Mann–Whitney U test with
respect to data distribution. Correlation analysis was con-
ducted with Spearman or Pearson’s test with respect to data
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123type and distribution. In case of association between
MMP-3 and PCDAI, due to nonlinear distribution of
data, a regression analysis was applied [y =- 1.1652 ?
0.9324x ? (-0.01285x
2), where y = MMP-3, x =
PCDAI] and a coefﬁcient of determination (R
2) calculated.
Tukey test was used for the detection of outliers. Differ-
ences in incidence rates were analyzed with Fisher’s exact
test. All tests were two-sided and P values B 0.05 were
considered signiﬁcant.
The diagnostic values of MMP-3, -9 and CRP were
evaluated using receiver operating characteristic (ROC)
curves analysis. The overall performance was expressed as
the area under ROC curve (AUC) with 95% CI and P sta-
tistics for the difference between calculated AUC and
AUC = 0.5 (marker without discriminative power). Cut-
off values corresponding to the highest accuracy were
determined and the related sensitivities and speciﬁcities
together with likelihood ratios for positive and negative
results (?LR and -LR) were calculated. Youden index
(sensitivity ? speciﬁcity - 1), a summary measure, was
calculated as well. Statistical analysis was conducted with
MedCalc
 version 11.4.4.0 statistical software.
Ethical Considerations
The study protocol was approved by the Medical Ethics
Committee of Wroclaw Medical University, Wroclaw,
Poland and the study was conducted in accordance with the
Helsinki Declaration of 1975, as revised in 1983.
Results
Metalloproteinase Concentrations and Disease Activity
Stage
Both MMP-3 (4.99 ng/ml, 95% CI: 3.54–7.01) and MMP-9
(7.15 ng/ml, 95% CI: 3.09–14.07) concentrations in the
sera of patients suffering from Crohn’s disease were higher
than those in the control group (1.95 ng/ml, 95% CI:
1.53–2.48, P\0.0001 and 1.30 ng/ml, 95% CI: 0.70–2.18,
P\001, respectively). However, our study showed dif-
ferent proﬁles of MMP-3 and -9 concentrations in sera of
children suffering from CD in different clinical activity
stages of CD. MMP-3 concentration was increasing up to
the moderate stage of the disease with a subsequent decline
in the severe stage (Fig. 1). The concentrations of MMP-3
in the severe and moderate groups were statistically higher
than in the mild and control groups (P\0.001). There
were no statistical differences between mild and control
groups.
In contrast to MMP-3, MMP-9 concentrations were
increasing along with the disease activity (Fig. 2). There
were statistically signiﬁcant differences between both the
moderate and severe groups and a mild group (P = 0.002).
Concentrations in the severe group exhibited the highest
values; however the differences between severe and mod-
erate groups did not reach statistical signiﬁcance. Con-
centration of MMP-9 in the moderate and severe groups
differed from those in the control group (P = 0.0001).
Table 1 Characteristics of the study group
Group Disease activity PCDAI Number of children Gender Age (years)
Females Males Range Mean
CD group Severe 55 (52.5–60)
a 9 9 0 2–16 12.6
Moderate 30 (27.5–32.3)
b 13 7 6 7–18 13.8
Mild 7.5 (5–11.6)
c 23 10 13 2–18 10.6
Total 45 26 19 2–18 11.9
Control group 37 23 14 1–18 10.1
CD Crohn’s disease, PCDAI pediatric Crohn’s disease activity index, PCDAI expressed as median values accompanied by 95% CI. Values with
the same superscripts do not differ statistically
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Fig. 1 MMP-3 concentration in serum with respect to the status of
Crohn’s disease activity in children. Closed circles represent MMP-3
concentration (ng/ml) in individual serum samples. Geometric mean
values accompanied by 95% CI are given for each group
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123Correlations Between MMP-3, -9 and the indices
of Crohn’s Disease
Concentrations of both metalloproteinases correlated with
each other (Table 2). There was a signiﬁcant correlation
between the concentrations of MMP-3 and disease activity
score (PCDAI) and ESR. MMP-3 correlated also with
seromucoid (r = 0.39, P = 0.009); however after the
implementation of Tukey test for outliers the correlation
lost its signiﬁcance (r = 0.23, P = 0.125). A weak, but not
statistically signiﬁcant correlation between MMP-3 con-
centrations and CRP was observed (q = 0.19, P = 0.183).
MMP-9 on the other hand correlated fairly well with
PCDAI, CRP and seromucoid (Table 2). There was also a
week, statistically not signiﬁcant correlation between
MMP-9 and ESR (q = 0.26, P = 0.088).
There was a strong positive correlation between PCDAI
and CRP, ESR and seromucoid (Table 2).
Performance of MMP-3 and -9 as Disease Markers
ROC analysis revealed that MMP-3 concentration indi-
cated CD presence with 75% accuracy using the concen-
tration of 4.2 ng/ml as an optimal cut-off value for
discrimination between patients with CD and controls
(95% CI: 0.642–0.839, P\0.0001). The likelihood ratios
of positive and negative results obtained on the basis of
optimal threshold values speciﬁc for CD were as follows:
?LR = 4.11 and –LR = 0.51 with sensitivity and speci-
ﬁcity equal to 56 and 87%, respectively. Youden index was
0.43.
In case of MMP-9 the calculated cut-off value for dis-
crimination between patients with CD and controls was
5.58 ng/ml and using this value the diagnostic accuracy
of MMP-9 was 73% (CI: 0.819–0.821, P\0.001). The
likelihood ratios of positive and negative results obtained
on the basis of optimal threshold values speciﬁc for CD
were as follows: ?LR = 5.14 and -LR = 0.50 with sen-
sitivity and speciﬁcity equal to 56 and 89%, respectively.
Youden index was 0.45.
We also evaluated diagnostic utility tests for CRP in the
cohort of our patients. Cut-off value was estimated as
4.3 mg/l. Using this value, diagnostic accuracy was 74%
(95% CI: 0.63–0.83, P\0.0001). The likelihood ratios of
positive and negative results obtained on the basis of
optimal threshold values speciﬁc for CD were as follows:
?LR = 8.56 and –LR = 0.54 with sensitivity and speci-
ﬁcity equal to 49 and 94%, respectively. Youden index was
0.43.
Discussion
To the best of our knowledge our study demonstrates for
the ﬁrst time a correlation between Crohn’s disease activity
in children and MMP-3 and -9 concentrations in serum.
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Fig. 2 MMP-9 concentration (ng/ml) in serum with respect to the
status of Crohn’s disease activity in children. Closed circles represent
MMP-9 concentration in individual serum samples. Median values
accompanied by 95% CI are given for each group
Table 2 Associations between MMP-3 and -9 and Crohn’s disease indices
Metalloproteinases MMP-3 MMP-9 PCDAI CRP ESR Seromucoid
MMP-3 q = 0.43* R
2 = 0.174* q = 0.19 r = 0.32* r = 0.23
a
P = 0.003 P = 0.018 P = 0.183 P = 0.035 P = 0.1253
MMP-9 q = 0.411* q = 0.45* q = 0.26 q = 0.42*
P = 0.005 P = 0.002 P = 0.088 P = 0.004
PCDAI q = 0.73* q = 0.73* q = 0.68*
P\0.0001 P\0.0001 P\0.0001
PCDAI pediatric Crohn’s disease activity index, CRP C reactive protein, ESR erythrocyte sedimentation rate
q Spearman correlation coefﬁcient, r Pearson correlation coefﬁcient, R
2 coefﬁcient of determination [y =- 1.1652 ? 0.9324x ? (-0.01285x
2),
where y = MMP3, x = PCDAI; F = 4.41]
* Statistically signiﬁcant correlations
a Tukey test
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123Local MMPs concentrations in histological specimens
from various parts of the alimentary tract affected by
inﬂammation have been found to correlate with histologi-
cal changes. This is especially true with respect to MMP-3
and -9, which are emerging as the main metalloproteinases
implicated in the development of IBD. Higher expression
of MMPs in inﬂammatory altered tissues has been dem-
onstrated by Meijer et al. [13]. They demonstrated
increased expression of MMP-1, -2, -3 and -9 in samples
affected by inﬂammation in comparison with those without
inﬂammation from both healthy subjects and IBD patients.
These results were corroborated by Louis et al. [12] and
von Lampe et al. [14] who observed signiﬁcant increases in
MMP-3 in inﬂammatory altered specimens from IBD
patients in comparison with the unaltered specimens as
well as with a control group. Similar results were obtained
in the comprehensive study of Pedersen et al. [32], who
found elevated expression of MMP-1, -3 -7, -9 and -10 in
the inﬂamed colonic epithelial cells from human mucosa.
Several studies have also indicated that inhibition of
metalloproteinases was leading to the attenuation of
inﬂammation in the experimentally induced bowel
inﬂammation in animal models [15, 16] as well as to the
prevention of intestine destruction in the ex vivo fetal
human model [17, 33]. These studies unequivocally point
to the disturbance in the equilibrium between the synthesis
and degradation of metalloproteinases in patients suffering
from IBD. However, the invasive procedures required for
the measurement of local concentrations of proteases in the
inﬂammatory altered tissues preclude the application of
these determinations in the continuous monitoring of the
disease course. Therefore, in our studies, we explored the
reliability of metalloproteinase measurements in serum.
We conducted the estimations in serum and not in plasma,
which might be considered a limitation of the study. It is
known that platelets are actively scavenging various factors
in order to release them when necessary, for example, at
the site of inﬂammation. However, in vitro, during clotting
of blood a degranulation of platelets takes place and the
factors entrapped there are released into serum. Hence, it
has been suggested that serum and not plasma reﬂects the
true potential of factors that can be stored by platelets, and
metalloproteinases are one of them [34].
We demonstrated that the concentrations of the studied
MMPs in serum, especially MMP-9, fairly well correlate
with the disease activity estimated using PCDAI index.
PCDAI index is characterized by a high degree of com-
plexity due to the analysis of many laboratory parameters
and clinical symptoms. The indices of endoscopic alter-
nations such as Crohn’s Disease Endoscopic Index of
Severity (CDEIS) and Simple Endoscopic Score for Cro-
hn’s Disease (SES-CD), which are used in the evaluation of
the intensity of changes in CD have a limited application
because of the invasiveness of procedure, and hence cannot
be used in frequent and repeated monitoring of patients
[35]. Therefore, the possibility of using a measurement of a
single parameter, such as for instance MMPs, in the easily
available biological material, seems to be of high impor-
tance. Our studies demonstrated statistically signiﬁcant
differences in the concentrations of the studied metallo-
proteinases in serum of patients with an active inﬂamma-
tory process taking place in the alimentary tract in the
course of Crohn’s disease in comparison to the control
group. The concentrations of MMP-9 were increasing
along with the disease progression with the lowest values
in patients with a mild type of disease, higher in the group
with moderate type of disease and highest in severe type of
disease.
MMP-9 better correlated with the indices of disease than
MMP-3. This is partially due to the fact that MMP-3 did
not exhibit linear correlation with the disease activity,
declining in the severe phase of CD, while the other studied
parameters had linear correlations. MMP-9 signiﬁcantly
correlated with PCDAI, CRP and seromucoid. The corre-
lation between MMP-9 and PCDAI was not very high;
however it has been previously noted that correlations
between laboratory indices of inﬂammation and clinical
disease activity scores are not always strong, since the
latter contain several components, some of which are
subjective in nature [31, 35]. Nevertheless, when evaluat-
ing diagnostic utility of MMP-3, -9 and CRP, their per-
formances in terms of both diagnostic accuracy and
Youden index are comparable with the notion that MMP-9
had higher sensitivity and CRP higher speciﬁcity. It has to
be noted, however, that diagnostic accuracy of CRP was
based on our cohort of pediatric patients and it was better
than reported elsewhere, for example, by Langhorst et al.
[36] (74% vs. 64%) for adult patients.
Despite the fact that the possibility of metalloproteinase
measurement in tissues other than locally collected tissue
specimens from the alimentary tract signiﬁcantly increases
the availability of such determinations in everyday medical
practice, the number of papers dedicated to this topic is
limited. Manfredi et al. [37], in their studies conducted on
the population of children and young adults with active
course of IBD, found that the concentrations of MMP-2
and -9 in the urine of patients with CD and UC differed
signiﬁcantly from a control group, and concluded that the
determinations of these metalloproteinases could be useful
as biomarkers in the evaluation of clinical activity of IBD.
Recently, the diagnostic utility of MMP-3 and -9 has been
evaluated in the sera of patients with colorectal cancer [38,
39]. Mroczko et al. [38], found MMP-9 determinations in
serum to be potentially useful in the differentiation
between colorectal cancer patients and healthy subjects
with a diagnostic accuracy of 55.9% and sensitivity of
710 Dig Dis Sci (2012) 57:706–712
12355%. Conversely, Yeh et al. [39], who studied MMP-3, -7
and -9 in the sera of H. pylori-infected gastric cancer
patients, did not ﬁnd differences in MMP-9 concentrations
between cancer patients and those suffering from gastritis
or duodenal or gastric ulcers; nevertheless they observed
that concomitant estimations of MMP-3 and -7 could serve
as indicators of lymph node invasion and poor survival. It
is worth mentioning that overall performance of both
MMP-3 and -9 in our studies was a much better indicator
that these metalloproteinases might be more useful in the
management of IBD than cancers.
The evidence of the elevated levels of metalloprotein-
ases in various kinds of biological materials broadens the
spectrum of the possible measurements, and what is most
important indicates that the studied metalloproteinases can
be used as biomarkers of disease activity in the course of
IBD. Especially the determinations of MMP-9, the con-
centrations of which were in a direct, linear relation to the
disease activity computed on the basis of clinical scales of
disease activity seem to create such a possibility. The fact
that MMP-3 is at ﬁrst increasing along with the disease
activity up to the moderate level with the subsequent drop
in its concentration in the severe form of CD seems to
indicate that this metalloproteinase is less useful as a single
indicator in the differentiation between moderate and
severe forms of the disease. This phenomenon observed in
our studies has not been described previously. However, in
other studies the patients were classiﬁed according to the
presence or absence of the inﬂammatory changes in the
histological mucosa specimens collected from a given
segment of intestinal tract. In our work the classiﬁcation
was based on the evaluation of clinical status of patients,
and from the entire group of patients distinct subgroups of
patients with mild, moderate and severe disease forms were
separated. With respect to our results it is, however, worth
mentioning that Kirkegaard et al. [40] studying the
expression of metalloproteinases in ﬁstulas in IBD patients
demonstrated elevated expression of MMP-9 transcripts in
an acute inﬂammation in the comparison with a chronic
one, whereas at the same time the expression of MMP-3
has been elevated in tissues affected by a chronic process.
Despite the fact that a direct comparison between a severe
form of disease estimated on the basis of clinical evaluation
and histologically conﬁrmed acute inﬂammation as well as
moderate disease and chronic inﬂammation is not possible,
a trend that in acute states MMP-9 is more elevated that
MMP-3 is noticeable.
The results of our studies indicate that the intensity of
the disease process taking place in the intestinal tract is
reﬂected by metalloproteinase concentrations in the blood.
These zinc proteases are one of the elements of inﬂam-
matory cascade causing a systemic reaction of the organ-
ism. However, the position of metalloproteinases in
inﬂammatory cascade limits their speciﬁcity with respect to
IBD. Yet, demonstrated in our study, relatively high, and
comparable with that of others, commonly used indices,
speciﬁcity of the studied metalloproteinases with respect to
Crohn’s disease severity creates the grounds for their
potential application, possibly in combination with other
factors, as indicators of this disease activity that might
prove useful in the monitoring of the disease course.
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